methyl N-hex-5-en-1-ylglycinate | 855509-03-4

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: methyl N-hex-5-en-1-ylglycinate
• 英文别名: methyl hex-5-en-1-ylglycinate；Methyl 2-(hex-5-enylamino)acetate；methyl 2-(hex-5-enylamino)acetate
• CAS: 855509-03-4
• 化学式: C₉H₁₇NO₂
• 分子量: 171.239
• InChiKey: SCPJAUGAIUQJSD-UHFFFAOYSA-N

物化性质

• 沸点：
  231.1±33.0 °C(Predicted)
• 密度：
  0.928±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  12
• 可旋转键数：
  8
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  38.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  methyl N-hex-5-en-1-ylglycinate 在 RuCl2(1,3-dimesityl-imidazolidin-2-yl)(PCy3)(=CHPh) 作用下， 以 甲醇 、 甲苯 为溶剂， 反应 96.0h， 生成
  参考文献：
  名称：

  烯丙基羟基膦酸酯：多功能手性构件

  摘要：

  使用一系列钯催化的反应，将烯丙基羟基膦酸酯转化为β和γ取代的氨基膦酸酯。氮亲核试剂和钯催化剂的明智选择可以实现出色的区域和立体化学控制。钯（0）催化的胺加成或甲苯磺酸氨基甲酸酯重排产生γ-取代的膦酸酯，而甲苯磺酸氨基甲酸酯与钯（II）和碱的反应产生恶唑烷酮（β-取代）。

  DOI：

  10.1016/j.jorganchem.2004.11.019
• 作为产物：
  描述：

  5-己烯-1-醇 在 molecular sieve 、 sodium cyanoborohydride 、 pyridinium chlorochromate 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 反应 26.0h， 生成 methyl N-hex-5-en-1-ylglycinate
  参考文献：
  名称：

  烯丙基羟基膦酸酯：多功能手性构件

  摘要：

  使用一系列钯催化的反应，将烯丙基羟基膦酸酯转化为β和γ取代的氨基膦酸酯。氮亲核试剂和钯催化剂的明智选择可以实现出色的区域和立体化学控制。钯（0）催化的胺加成或甲苯磺酸氨基甲酸酯重排产生γ-取代的膦酸酯，而甲苯磺酸氨基甲酸酯与钯（II）和碱的反应产生恶唑烷酮（β-取代）。

  DOI：

  10.1016/j.jorganchem.2004.11.019

文献信息

• Nucleic acid comprising zwitterionic nucleotides
  申请人：novosom AG

  公开号：EP2143726A1

  公开（公告）日：2010-01-13

  This invention provides pH-responsive zwitterionic nucleotides and nucleic acids comprising said nucleotides, wherein said zwitterions are constituted from one or more anionic internucleoside linkages and one or more cationic moieties and said zwitterionic nucleotides further comprise either one or more hydrophobic moieties or one or more TEE's with the general structure (I) Hydrophobic element - pH-responsive hydrophilic elements (I).

  本发明提供了 pH 响应型齐聚物核苷酸和包含所述核苷酸的核酸，其中所述齐聚物由一个或多个阴离子核苷内连接和一个或多个阳离子分子构成，所述齐聚物核苷酸进一步包含一个或多个疏水分子或一个或多个 TEE，其一般结构为 (I) 疏水元件--pH 响应亲水元件 (I)。
• Application of ring-closing metathesis macrocyclization to the development of Tsg101-binding antagonists
  作者：Fa Liu、Andrew G. Stephen、Abdul A. Waheed、Eric O. Freed、Robert J. Fisher、Terrence R. Burke

  DOI：10.1016/j.bmcl.2009.10.105

  日期：2010.1

  HIV-1 viral budding involves binding of the viral Gag(p6) protein to the ubiquitin E2 variant domain of the human tumor susceptibility gene 101 protein (Tsg101). Recognition of p6 by Tsg101 is mediated in part by a proline-rich motif that contains the sequence 'Pro-Thr-Ala-Pro' ('PTAP'). Using the p6-derived 9-mer sequence 'PEPTAPPEE', we had previously improved peptide binding affinity by employing N-alkylglycine ('peptoid') residues. The current study applies ring-closing metathesis macrocyclization strategies to Tsg101-binding peptide-peptoid hybrids as an approach to stabilize binding conformations and to observe the effects of such macrocyclization on Tsg101-binding affinity and bioavailability. Published by Elsevier Ltd.
• MACROCYCLIC COMPOUNDS AND THEIR USE IN THE TREATMENT OF DISEASE
  申请人：Novartis AG

  公开号：EP3898621A1

  公开（公告）日：2021-10-27
• WATER-SOLUBLE PRODRUGS
  申请人：BOSTON BIOMEDICAL, INC.

  公开号：US20180111914A1

  公开（公告）日：2018-04-26

  The present invention provides compounds represented by formula (1A), or pharmaceutically acceptable salts. Compounds represented by formula (1A), or pharmaceutically acceptable salts thereof, wherein A 1 and A 2 are identical or different, and each independently —C(═O) B, —C(═O)CR 3A R 3B B, —CO 2 B, —C(═S)OB, —CONR 3C B, —C(═S)NR 3C B, a hydrogen atom, or the like, wherein A 1 and A 2 are not both hydrogen atoms, wherein B is an optionally substituted 3- to 12-membered monocyclic or polycyclic heterocyclic group, an optionally substituted 3- to 12-membered cyclic amino group, or a group represented by the following formula (B), wherein the 3- to 12-membered monocyclic or polycyclic heterocyclic group and the 3- to 12-membered cyclic amino group have at least one or more secondary nitrogen atoms in the ring; R 1 is a hydrogen atom or the like; R 2A , R 2B , R 2C , and R 2D are identical or different, and each independently a hydrogen atom or the like; and R 8 is alkyl. wherein * denotes a bonding position.
• [EN] MACROCYCLIC COMPOUNDS AND THEIR USE IN THE TREATMENT OF DISEASE<br/>[FR] COMPOSÉS MACROCYCLIQUES ET LEUR UTILISATION DANS LE TRAITEMENT DE MALADIES
  申请人：NOVARTIS AG

  公开号：WO2020128925A1

  公开（公告）日：2020-06-25

  The invention relates to heterocyclic compounds of the formula (I), in which all of the variables are as defined in the specification; capable of modulating the activity of CFTR. The invention further provides a method for manufacturing compounds of the invention, and its therapeutic uses. The invention further provides methods to their preparation, to their medical use, in particular to their use in the treatment and management of diseases or disorders including Cystic fibrosis and related disorders.